Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease
- Vande Casteele, Niels
- Ferrante, Marc
- Van Assche, Gert
- Ballet, Vera
- Compernolle, Griet
- Van Steen, Kristel
- Simoens, Steven
- Rutgeerts, Paul
- Gils, Ann
- Vermeire, Séverine
Publication date
June 2015
DOI Publisher
W.B. Saunders ISSN
0016-5085 Journal
issn:1528-0012 Citation count (estimate)
229Abstract
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC.status: publishe
Add to ORKG